Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Switzerland

European Research Council grant · Running

BIOTRANS Biological permeation enhancers for transbuccal drug delivery

Coordinator
Eidgenoessische Technische Hochschule Zuerich, Switzerland
Runs
1 January 2027 to 30 June 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101322838

What the project is doing

In the project's own words, from its summary on CORDIS.

Peptide drugs hold immense therapeutic potential but are primarily restricted to injectable administration due to poor permeability across biological barriers. While conventional permeation enhancers (PEs) have enabled oral absorption for a few peptides, their broader application remains constrained by limited efficacy. Developing a novel, potent class of PEs would provide a patient-friendly alternative to injections, expanding access to peptide therapies and improving treatment acceptance.

This project aims to establish enzymatic PEs as a strategy for non-invasive transbuccal macromolecular drug delivery as a proof-of-concept application. Membrane-degrading enzymes will be evaluated alone and in combination for their ability to transiently enhance drug diffusion across the buccal mucosa. The project follows a stepwise validation approach, incorporating in vitro, ex vivo, and in vivo studies in dogs to ensure robust and clinically relevant evaluation of the PE performance.

A substantial increase in bioavailability compared to current buccal formulations using conventional PEs will be the key translational benchmark to establish the superiority of enzymatic PEs for non-invasive peptide delivery. Upon successful validation, intellectual property protection will be pursued, and collaboration with industrial partner(s) will drive commercial development, positioning these PEs as a transformative technology for convenient peptide dosing.

By leveraging enzymatic specificity with innovative delivery approaches, this project aims to address critical clinical and societal challenges, enhancing accessibility to macromolecule-based therapies while reducing reliance on invasive administration modes.

Topics

Who is involved

OrganisationCityCountryRole
Eidgenoessische Technische Hochschule ZuerichZuerichSwitzerlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI